Course handouts are now available
Click here
Come to London
WATCH to find out why
Site updates:
Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.
Posters
(results will display both Free Papers & Poster)
Twelve month results after stand-alone implantation of CyPass Micro-Stent in patients with open-angle glaucoma in Bulgaria
Poster Details
First Author: T.Ianchulev USA
Co Author(s): P. Guguchkova B. Samsonova A. Topov
Abstract Details
Purpose:
To evaluate the CyPass Micro-Stent (Transcend Medical, Inc., Menlo Park, CA, USA), a supraciliary, ab interno implant, as a standalone treatment for patients with open-angle glaucoma (OAG) unresponsive to topical therapies in a single center in Bulgaria.
Setting:
Single-center, interventional, prospective, consecutive case series
Methods:
The implant was placed ab interno through a corneal incision under gonioscopic visualization as a standalone procedure. Medications were stopped following the procedure and re-introduced per the investigator's decision and the subject's intraocular pressure (IOP) target. Main outcomes were adverse events, IOP changes, and number of IOP-lowering medications at baseline and 1 year.
Results:
Eyes (n=17) were enrolled. There were no major adverse events. High IOP occurred in 3 subjects (17.6%). Transient hypotony occurred in 1 subject (5.9%) but was resolved in the first month. At baseline, subjects had mean ± SD baseline IOP (n=17) was 24.2 ± 5.2 mmHg and mean ± SD medication usage was 2.1 ± 1.1 medications. At 12 months, subjects had a mean ± SD IOP of 17.6 ± 5.4 mmHg (n=15), representing a 23% reduction, with mean ± SD medication usage of 1.3 ± 0.9 medications.
Conclusions:
The CyPass Micro-Stent is a safe and effective standalone treatment for open-angle glaucoma patients unresponsive to medications. FINANCIAL INTEREST: One of more of the authors... is employed by a forNONEprofit company with an interest in the subject of the presentation, One of more of the authors... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, One of more of the authors... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented